DSIP 5 mg
What is on file for this vial.
Brand
Maker not published for this row — sold in the supplier's own packaging.
Lab reports
No third-party COA held for this row — verification pending, nothing implied.
Questions about this vial.
What is in one unit?
One unit is VIAL, as stated upstream. The price on this page is quoted for that unit.
Who wrote the description above?
The supplier, and what they publish for this vial is unusually short. We print what they wrote rather than filling the gap ourselves; the specification and the paperwork below are the parts we can stand behind.
Is there a lab report for this vial?
No third-party lab report is published for this line, so this page carries none — we would rather leave the section empty than print a certification we cannot back. Where a report does exist, it is published on the product page it belongs to, under Batch documentation, with the lab, the batch, the measured values and the verification key you can check at the lab. For this line, send us your order number and the batch printed on your box and we request that batch's paperwork from the supplier.
How is it shipped, and how fast?
Payment clearing on a working day means same-day dispatch, and most parcels arrive in about 4 days, tracked, inside the European Union, in an unmarked box. One flat €20.00 per order. Nothing ships refrigerated — lyophilised peptide holds at room temperature in transit.
Can I return it?
Unopened, seal intact, within 14 days of delivery, at your postage cost. An opened or reconstituted vial cannot come back — nobody can verify what is in it or how it was kept.
What is this sold for?
In-vitro laboratory research, nothing else. Not for human or veterinary use; nothing on this page is medical advice, a dosing protocol or a recommendation.
On file.
| Form | VIAL |
| SKU | ZX-019 |
| Category | Neuro & Sleep |
| Department | PEPTIDE |
What researchers reported.
Nothing reported on this vial yet. If you have worked with it, yours is the first.
From the research desk.
Claims we checkedDSIP: the one controlled human trial ended in a negative result
Sixteen chronic insomniacs received 25 nmol/kg of DSIP intravenously in a double-blind matched-pairs design across three nights, and the authors concluded it is not likely to be of major therapeutic benefit because the significant effects were weak. The recent pharmacology is mice. This page reports both.
RepairDSIP: the peptide named for sleep, and what it was measured doing
Isolated from rabbit blood in 1977 and named for slow-wave sleep, DSIP reduced slow-wave sleep in cats when it was actually tested. The sleep hypothesis has been described in the peer-reviewed literature as extremely poorly documented and still weak.
HormonalSleep loss and the growth hormone axis
Cutting sleep measurably suppresses growth hormone output in people, and none of the three sleep peptides in this catalogue has been shown in a human trial to change it.
